Abstracts tagged "ANCA"

Abstract Number: 1773 • 2017 ACR/ARHP Annual Meeting
New Use for an Old Drug: Hydroxychloroquine for the Treatment of ANCA Associated Vasculitis
Alina Casian¹, Rachel Jones², Ruzaika Cader³, Alan D. Salama⁴, Shirish Sangle⁵, David Jayne⁶ and David P. D'Cruz⁷, ¹Lupus Unit, Guy's Hospital, London, United Kingdom, ²Nephrology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Nephrology, Norfolk and Norwich Hospitals, Norfolk, United Kingdom, ⁴Centre for Nephrology, University College London, London, United Kingdom, ⁵Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ⁶Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ⁷Louise Coote Lupus Unit, Rheumatology and Lupus, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: To assess retrospectively the efficacy and safety of hydroxychloroquine in patients with ANCA associated vasculitis. There is an unmet need for a corticosteroid sparing, non-toxic…
Abstract Number: 1750 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular and Thrombotic Disease Among Patients with Incident ANCA-Associated Vasculitis: A 20 Year Population Based Cohort Study
Alvise Berti^1,2, Eric L. Matteson^3,4, Cynthia S. Crowson^5,6, Ulrich Specks⁷ and Divi Cornec^8,9, ¹Department of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, ²Department of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milan, Italy, ³Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Department of Health Sciences Research, Division of Epidemiology, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁶Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁷Mayo Clinic College of Medicine, Rochester, MN, ⁸Department of Rheumatology, Brest Teaching Hospital, Brest, France, ⁹Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: ANCA-associated vasculitides (AAV) are characterized by inflammation and necrosis of small-sized vessels. Because cardiovascular disease (CVD) is a leading contributor to morbidity and mortality,…
Abstract Number: 1776 • 2017 ACR/ARHP Annual Meeting
Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan
Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: The combination of immunosuppressants and glucocorticoid is recommended for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, adverse events of immunosuppressants sometimes…
Abstract Number: 1751 • 2017 ACR/ARHP Annual Meeting
Association of a TNFSF4 Upstream Region Single Nucleotide Polymorphism with Susceptibility to Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Yuka Iwahashi¹, Aya Kawasaki¹, Fumio Hirano², Ken-ei Sada³, Daisuke Tsukui⁴, Yuya Kondo⁵, Shigeto Kobayashi⁶, Hidehiro Yamada⁷, Hiroshi Furukawa¹, Kenji Nagasaka⁸, Takahiko Sugihara⁹, Kunihiro Yamagata¹⁰, Takayuki Sumida⁵, Shigeto Tohma¹¹, Hajime Kono⁴, Shoichi Ozaki⁷, Seiichi Matsuo¹², Hiroshi Hashimoto¹³, Hirofumi Makino¹⁴, Yoshihiro Arimura¹⁵, Masayoshi Harigai¹⁶ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ²Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ⁶Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁷Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁸Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ⁹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁰Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ¹¹Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ¹²Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹³Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Okayama University Hospital, Okayama, Japan, ¹⁵First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁶Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: In the epidemiology of ANCA-associated vasculitis (AAV), an obvious difference between European and Asian populations has been reported. According to the clinical classification, granulomatosis…
Abstract Number: 1778 • 2017 ACR/ARHP Annual Meeting
Prophylactic Treatment and Incidence of Pneumocystis Jirovecci Pneumonia in Japanese Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Izaya Nakaya¹, Ken-ei Sada², Jun Soma¹, Yoshihiro Arimura³, Masayoshi Harigai⁴, Kunihiro Yamagata⁵, Hirofumi Makino⁶ and Seiichi Matsuo⁷, ¹Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ⁴Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ⁶Okayama University Hospital, Okayama, Japan, ⁷Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Pneumocystis jiroveciipneumonia (PCP) is a fatal complication in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). However, the current situation of prophylactic treatment of PCP and its…
Abstract Number: 1752 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis
Divi Cornec¹, Brian Kabat¹, John Mills¹, Melissa Cheu², Amber Hummel¹, Darrell Schroeder¹, Matthew Cascino³, Paul Brunetta³, David Murray¹, Melissa Snyder¹, Fernando Fervenza¹, Gary S. Hoffman⁴, Cees G.M. Kallenberg⁵, Carol A. Langford⁶, Peter A. Merkel⁷, Paul A. Monach⁸, Philip Seo⁹, Robert F. Spiera¹⁰, E. William St Clair¹¹, John H. Stone¹², David Barnidge¹ and Ulrich Specks¹³, ¹Mayo Clinic, Rochester, MN, ²Genentech Inc., South San Francisco, CA, ³Genentech, Inc., South San Francisco, CA, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, MN, ⁸Boston University School of Medicine, Boston, MA, ⁹Medicine, Johns Hopkins University, Baltimore, MD, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Rheumatology, Duke University Medical Center, Durham, NC, ¹²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹³Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Response to rituximab (RTX) is variable in patients with ANCA-associated vasculitis (AAV), and predictors of treatment efficacy/relapse risk would be useful. Previous studies have…
Abstract Number: 1844 • 2017 ACR/ARHP Annual Meeting
Circulating Cytokine Profiles Reflect ANCA Specificity in Patients with ANCA-Associated Vasculitis
Alvise Berti¹, Roscoe Warner², Kent Johnson³, Divi Cornec⁴, Darrell Schroder⁵, Brian Kabat⁵, Peter A. Merkel⁶, Carol A. Langford⁷, Gary S. Hoffman⁸, Cees G.M. Kallenberg⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene St. Clair¹², John H. Stone¹³, Ulrich Specks¹⁴ and Paul A. Monach¹⁵, ¹Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ²University of Michigan Medical School, Ann Arbor,, MI, ³University of Michigan Medical School, Ann Arbor, MI, ⁴Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, Cleveland Clinic, Cleveland, OH, ⁹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²Department of Medicine, Duke University Medical Center, Durham, NC, ¹³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹⁴Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Boston University School of Medicine, Boston, MA
Background/Purpose: To evaluate serum cytokine and chemokine profiles in patients with ANCA-associated vasculitis (AAV) classified by ANCA specificity (proteinase 3 (PR3)-ANCA versus myeloperoxidase (MPO)-ANCA) or…
Abstract Number: 1755 • 2017 ACR/ARHP Annual Meeting
Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis
Hiromichi Tamaki¹, Robert Butler² and Carol A. Langford³, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
Background/Purpose: Low-dose trimethoprim-sulfamethoxazole (LDTS, 160mg-800mg 3x/week or 80mg-400mg/day) is effective for prevention of Pneumocystis jiroveci pneumonia (PCP), a serious opportunistic infection seen in patients with…
Abstract Number: 1846 • 2017 ACR/ARHP Annual Meeting
Increased CD38hiCD27+ Plasmablast Frequency in Remission Predicts Relapsing Disease in Granulomatosis with Polyangiitis Patients
Anouk von Borstel¹, Wayel H. Abdulahad², Abraham Rutgers², Judith Land², Coen A. Stegeman¹, Peter Heeringa³ and Jan-Stephan F. Sanders¹, ¹Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Patients with granulomatosis with polyangiitis (GPA) are prone to disease relapse. Changes in anti-neutrophil cytoplasmic autoantibodies (ANCA) levels can predict relapses in individual patients…
Abstract Number: 16L • 2016 ACR/ARHP Annual Meeting
Comparison of Systematic Vs Individually Tailored Rituximab Regimen to Maintain ANCA-Associated–Vasculitis Remission: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Pierre Charles¹, Benjamin Terrier², Pascal Cohen³, Stanislas Faguer⁴, Antoine Huart⁵, Mohamed Hamidou⁶, Christian Agard⁷, Bernard Bonnotte⁸, Maxime Samson⁸, Alexandre Karras⁹, Noémie Jourde-Chiche¹⁰, François Lifermann¹¹, Pierre Gobert¹², Catherine Hanrotel-Saliou¹³, Pascal Godmer¹⁴, Nicolas Martin Silva¹⁵, Grégory Pugnet¹⁶, Marie Matignon¹⁷, Olivier Aumaître¹⁸, Estibaliz Lazaro¹⁹, Luc Mouthon²⁰, Loïc Guillevin²¹ and French Vasculitis Study Group, ¹Service de Médecine Interne, Hôpital Cochin, Paris, France, ²Internal Medicine, Cochin University Hospital, Paris, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴2Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France, ⁵CHU, Toulouse, France, ⁶Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁸Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁹Nephrology, HEGP, Paris, France, ¹⁰Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ¹¹CH Dax, Dax, France, ¹²Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹³CHU Cavale Blanche, Brest, Brest, France, ¹⁴CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Caen University Hospital, Caen, France, ¹⁶Service de Médecine Interne, CHU de Toulouse, Toulouse, Toulouse, France, ¹⁷Service de Néphrologie, Hôpital Henri-Mondor, Créteil, Créteil, France, ¹⁸CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ¹⁹Service de Médecine Interne et Maladies Infectieuses, CHU de Bordeaux, Pessac, France, ²⁰Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France

Background/Purpose: Remission of ANCA-associated vasculitides (AAVs) can be induced with combined glucocorticoids and cyclophosphamide or rituximab (RTX) with comparable efficacy.1 RTX superiority to azathioprine was…
Abstract Number: 978 • 2016 ACR/ARHP Annual Meeting
A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis
Peter A. Merkel¹, John Niles², Richard Jimenez³, Robert F. Spiera⁴, Brad H. Rovin⁵, Andrew Bomback⁶, Christian Pagnoux⁷, Antonia Potarca⁸, Thomas J. Schall⁹ and Pirow Bekker⁹, ¹Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA, ²Massachusetts General Hospital, Boston, MA, ³Rheumatology, The Seattle Arthritis Clinic, University of Washington Medicine, Northwest Hospital and Medical Center, Seattle, WA, ⁴Hospital for Special Surgery, Cornell, New York, NY, ⁵Ohio State University Medical Center, Columbus, OH, ⁶Columbia University Medical Center, New York, NY, ⁷Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ⁸ChemoCentryx, Inc., Mountain View, CA, ⁹ChemoCentryx, Mountain View, CA
Background/Purpose: Complement 5a (C5a) is involved in the pathogenesis of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). CCX168 is an orally administered, small molecule selective inhibitor of…
Abstract Number: 1942 • 2016 ACR/ARHP Annual Meeting
Presentation and Clinical Features of ANCA-Associated Vasculitis in US African Americans: Experience from a Single Center
Sebastian Sattui¹, Andrew Westfall² and Angelo L. Gaffo³, ¹Tinsley Harrison Internal Medicine Residency Program, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, Birmingham VA Medical Center, Birmingham, AL
Title: Presentation and Clinical Features of ANCA-associated Vasculitis in US African Americans: Experience From a Single Center Background/Purpose: Little is known about the presentation,…
Abstract Number: 3179 • 2016 ACR/ARHP Annual Meeting
Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Joanna C. Robson^1,2,3, Jill Dawson⁴, Judy A. Shea⁵, Helen Doll⁶, Susan Ashdown⁷, Renee Borchin⁸, Ebony Easley⁹, John T. Farrar¹⁰, Don Gebhart¹¹, Katherine Kellom¹², Georgia Lanier¹³, Raashid Luqmani¹⁴, Carol A McAlear¹⁵, John Mills¹⁶, Nataliya Milman^17,18,19, Jacqueline Peck⁷, Gunnar Tomasson²⁰, Peter F. Cronholm⁹ and Peter A. Merkel²¹, ¹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ²Department of Rheumatology, University Hospitals Bristol NHS Trust, Bristol, United Kingdom, ³School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁴Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁵Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Department of Population Health, University of East Anglia, Norwich, United Kingdom, ⁷Oxford, Oxford, United Kingdom, ⁸University of South Florida, Tampa, FL, ⁹Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Columbus, Columbus, OH, ¹²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ¹³NONE, Framingham, MA, ¹⁴NDORMS , Rheumathology, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ¹⁵Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁶Vasculitis UK, Sheffield, United Kingdom, ¹⁷Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ¹⁸The Ottawa Hospital, Ottawa, ON, Canada, ¹⁹Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²⁰Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ²¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Candidate questionnaire items were produced following in-depth qualitative research in the UK, US, and Canada plus cognitive interviews, extensive piloting and independent linguistic and…
Abstract Number: 980 • 2016 ACR/ARHP Annual Meeting
Short-Course Glucocorticoids in ANCA-Associated Vasculitis: A Proof of Concept Study
Eli Miloslavsky¹, John Niles², Karen Laliberte², Katherine Cosgrove² and John H. Stone³, ¹Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Despite therapeutic advances in ANCA-associated vasculitis (AAV), patients continue to be exposed to considerable treatment morbidity from long-term glucocorticoid (GC) use. The optimal duration…
Abstract Number: 1943 • 2016 ACR/ARHP Annual Meeting
Factors Predictive of ANCA-Associated Vasculitis Relapse
Maxime Samson¹, Hervé Devilliers², Xavier Puéchal³, Christian Pagnoux⁴, Pascal Cohen³, Luc Mouthon³, Benjamin Terrier⁵ and Loïc Guillevin³, ¹Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: To identify associations between patients’ clinical and biological characteristics at diagnosis of antineutrophil cytoplasmic antibody-associated vasculitides (AAVs), and their relapse during follow-up. Methods: Long-term…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].